☰

Michael T. Lotze - Publications

Affiliations: 
University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Cell Biology, Immunology, Genetics, Oncology
Tree Info Grants Similar researchers PubMed Report error

327 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Perales-Linares R, Leli NM, Mohei H, Beghi S, Rivera OD, Kostopoulos N, Giglio A, George SS, Uribe-Herranz M, Costabile F, Pierini S, Pustylnikov S, Skoufos G, Barash Y, Hatzigeorgiou AG, ... ... Lotze MT, et al. Parkin deficiency suppresses antigen presentation to promote tumor immune evasion and immunotherapy resistance. Cancer Research. PMID 37578274 DOI: 10.1158/0008-5472.CAN-22-2499  0.303
2021 Giehl E, Kosaka H, Liu Z, Feist M, Kammula US, Lotze MT, Ma C, Guo ZS, Bartlett DL. Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy. Frontiers in Immunology. 12: 610042. PMID 33679747 DOI: 10.3389/fimmu.2021.610042  0.326
2020 Soloff AC, Jones KE, Powers AA, Murthy P, Wang Y, Russell KL, Byrne-Steele M, Lund AW, Yuan JM, Monaco SE, Han J, Dhupar R, Lotze MT. HMGB1 Promotes Myeloid Egress and Limits Lymphatic Clearance of Malignant Pleural Effusions. Frontiers in Immunology. 11: 2027. PMID 33013860 DOI: 10.3389/Fimmu.2020.02027  0.395
2020 Allen A, Gau D, Francoeur P, Sturm J, Wang Y, Martin R, Maranchie J, Duensing A, Kaczorowski A, Duensing S, Wu L, Lotze MT, Koes D, Storkus WJ, Roy P. Actin-binding protein Profilin1 promotes aggressiveness of clear cell renal cell carcinoma cells. The Journal of Biological Chemistry. PMID 32883810 DOI: 10.1074/Jbc.Ra120.013963  0.402
2020 Dhupar R, Okusanya OT, Eisenberg SH, Monaco SE, Ruffin AT, Liu D, Luketich JD, Kammula US, Bruno TC, Lotze MT, Soloff AC. Characteristics of Malignant Pleural Effusion Resident CD8 T Cells from a Heterogeneous Collection of Tumors. International Journal of Molecular Sciences. 21. PMID 32867034 DOI: 10.3390/Ijms21176178  0.39
2020 Huang J, Chen P, Liu K, Liu J, Zhou B, Wu R, Peng Q, Liu ZX, Li C, Kroemer G, Lotze M, Zeh H, Kang R, Tang D. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Gut. PMID 32816920 DOI: 10.1136/Gutjnl-2019-320441  0.329
2020 Zhang X, Deibert CP, Kim WJ, Jaman E, Rao AV, Lotze MT, Amankulor NM. Autophagy inhibition is the next step in the treatment of glioblastoma patients following the Stupp era. Cancer Gene Therapy. PMID 32759988 DOI: 10.1038/S41417-020-0205-8  0.328
2020 Guo ZS, Lotze MT, Zhu Z, Storkus WJ, Song XT. Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy. Biomedicines. 8. PMID 32664210 DOI: 10.3390/Biomedicines8070204  0.381
2020 Feist M, Zhu Z, Dai E, Ma C, Liu Z, Giehl E, Ravindranathan R, Kowalsky SJ, Obermajer N, Kammula US, Lee AJH, Lotze MT, Guo ZS, Bartlett DL. Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Therapy. PMID 32632271 DOI: 10.1038/S41417-020-0189-4  0.402
2020 Brufsky A, Marti JLG, Nasrazadani A, Lotze MT. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. Journal of Translational Medicine. 18: 261. PMID 32600410 DOI: 10.1186/S12967-020-02433-6  0.31
2020 Brufsky A, Lotze MT. DC/L-SIGNs of Hope in the COVID-19 Pandemic. Journal of Medical Virology. PMID 32374430 DOI: 10.1002/Jmv.25980  0.3
2020 Ramirez JAZ, Romagnoli GG, Falasco BF, Gorgulho CM, Fogolin CS, Santos DCD, Junior JPA, Lotze MT, Ureshino RP, Kaneno R. Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate. International Immunopharmacology. 84: 106495-106495. PMID 32298965 DOI: 10.1016/J.Intimp.2020.106495  0.43
2020 Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, ... ... Lotze MT, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal For Immunotherapy of Cancer. 8. PMID 32209603 DOI: 10.1136/Jitc-2019-000337  0.355
2020 Kang R, Zeh H, Lotze M, Tang D. The Multifaceted Effects of Autophagy on the Tumor Microenvironment. Advances in Experimental Medicine and Biology. 1225: 99-114. PMID 32030650 DOI: 10.1007/978-3-030-35727-6_7  0.422
2020 Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, ... Lotze MT, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: 1902-1913. PMID 31566658 DOI: 10.1093/Annonc/Mdz398  0.336
2020 Han J, Lotze MT. The Adaptome as Biomarker for Assessing Cancer Immunity and Immunotherapy. Methods in Molecular Biology (Clifton, N.J.). 2055: 369-397. PMID 31502161 DOI: 10.1007/978-1-4939-9773-2_17  0.342
2020 Fei N, Wen S, Rao P, Ramanathan R, Hogg ME, Zureikat AH, Lotze MT, Bahary N, Singhi AD, Zeh H, Boone BA. Association of SMAD4 loss with response to neoadjuvant chemotherapy with the autophagy inhibitor hydroxychloroquine in patients with pancreatic adenocarcinoma. Journal of Clinical Oncology. 38: 761-761. DOI: 10.1200/Jco.2020.38.4_Suppl.761  0.369
2019 Murthy P, Zenati MS, Al Abbas AI, Rieser CJ, Bahary N, Lotze MT, Zeh HJ, Zureikat AH, Boone BA. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Annals of Surgical Oncology. PMID 31792715 DOI: 10.1245/S10434-019-08094-0  0.344
2019 Mendonça Gorgulho C, Murthy P, Liotta L, Espina V, Lotze MT. Different measures of HMGB1 location in cancer immunology. Methods in Enzymology. 629: 195-217. PMID 31727241 DOI: 10.1016/Bs.Mie.2019.10.011  0.345
2019 Soloff AC, Lotze MT. A peaceful death orchestrates immune balance in a chaotic environment. Proceedings of the National Academy of Sciences of the United States of America. PMID 31653759 DOI: 10.1073/Pnas.1916211116  0.333
2019 Miller-Ocuin JL, Liang X, Boone BA, Doerfler WR, Singhi AD, Tang D, Kang R, Lotze MT, Zeh HJ. DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth. Oncoimmunology. 8: e1605822. PMID 31428515 DOI: 10.1080/2162402X.2019.1605822  0.385
2019 Tandon M, Coudriet GM, Criscimanna A, Socorro M, Eliliwi M, Singhi AD, Cruz-Monserrate Z, Bailey P, Lotze MT, Zeh H, Hu J, Goffin V, Gittes GK, Biankin AV, Esni F. Prolactin promotes fibrosis and pancreatic cancer progression. Cancer Research. PMID 31395607 DOI: 10.1158/0008-5472.Can-18-3064  0.374
2019 Gorgulho CM, Romagnoli GG, Bharthi R, Lotze MT. Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1. Frontiers in Immunology. 10: 1561. PMID 31379812 DOI: 10.3389/Fimmu.2019.01561  0.339
2019 Yang M, Chen P, Liu J, Zhu S, Kroemer G, Klionsky DJ, Lotze MT, Zeh HJ, Kang R, Tang D. Clockophagy is a novel selective autophagy process favoring ferroptosis. Science Advances. 5: eaaw2238. PMID 31355331 DOI: 10.1126/Sciadv.Aaw2238  0.385
2019 Li G, Sachdev U, Peters K, Liang X, Lotze MT. The VE-PTP Inhibitor AKB-9778 Improves Antitumor Activity and Diminishes the Toxicity of Interleukin 2 (IL-2) Administration. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 31348125 DOI: 10.1097/Cji.0000000000000290  0.369
2019 Russell KL, Gorgulho CM, Allen A, Vakaki M, Wang Y, Facciabene A, Lee D, Roy P, Buchser WJ, Appleman LJ, Maranchie J, Storkus WJ, Lotze MT. Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium. Cancer Journal (Sudbury, Mass.). 25: 165-177. PMID 31135523 DOI: 10.1097/Ppo.0000000000000374  0.388
2019 Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, ... ... Lotze MT, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal For Immunotherapy of Cancer. 7: 131. PMID 31113486 DOI: 10.1186/S40425-019-0602-4  0.376
2019 Boone BA, Murthy P, Miller-Ocuin JL, Liang X, Russell KL, Loughran P, Gawaz M, Lotze MT, Zeh HJ, Vogel S. The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth. Annals of Hematology. PMID 31020347 DOI: 10.1007/S00277-019-03692-0  0.314
2019 Murthy P, Ekeke CN, Russell KL, Butler SC, Wang Y, Luketich JD, Soloff AC, Dhupar R, Lotze MT. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology. 8: e1554969. PMID 30906651 DOI: 10.1080/2162402X.2018.1554969  0.365
2019 Yurube T, Buchser WJ, Moon HJ, Hartman RA, Takayama K, Kawakami Y, Nishida K, Kurosaka M, Vo NV, Kang JD, Lotze MT, Sowa GA. Serum and nutrient deprivation increase autophagic flux in intervertebral disc annulus fibrosus cells: an in vitro experimental study. European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. PMID 30847707 DOI: 10.1007/S00586-019-05910-9  0.31
2019 Murthy P, Singhi AD, Ross MA, Loughran P, Paragomi P, Papachristou GI, Whitcomb DC, Zureikat AH, Lotze MT, Zeh Iii HJ, Boone BA. Enhanced Neutrophil Extracellular Trap Formation in Acute Pancreatitis Contributes to Disease Severity and Is Reduced by Chloroquine. Frontiers in Immunology. 10: 28. PMID 30733719 DOI: 10.3389/Fimmu.2019.00028  0.311
2019 Lotze MT, Appleman LJ, Zhai S, Wang YY, Forte A, Pan W, Byrne-Steele ML, Han J. Full adaptome repertoire analysis of immunotherapy to predict responsiveness and correlation with CD8-LAG3, sLAG3, and hepatocyte growth factor levels in patients with renal cancer. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E16116  0.309
2019 Wang Y, Lotze MT. Abstract 3963: Deep serial analysis of the TCR/BCR CDR3 adaptome repertoire in peripheral blood of pancreatic cancer patients in a randomized study of neoadjuvant chemotherapy with or without autophagy inhibition Cancer Research. 79: 3963-3963. DOI: 10.1158/1538-7445.Am2019-3963  0.346
2018 Li C, Zhang Y, Cheng X, Yuan H, Zhu S, Liu J, Wen Q, Xie Y, Liu J, Kroemer G, Klionsky DJ, Lotze MT, Zeh HJ, Kang R, Tang D. PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. Developmental Cell. PMID 30100261 DOI: 10.1016/J.Devcel.2018.07.012  0.337
2018 Song X, Zhu S, Chen P, Hou W, Wen Q, Liu J, Xie Y, Liu J, Klionsky DJ, Kroemer G, Lotze MT, Zeh HJ, Kang R, Tang D. AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System X Activity. Current Biology : Cb. PMID 30057310 DOI: 10.1016/J.Cub.2018.05.094  0.343
2018 Boone BA, Murthy P, Miller-Ocuin J, Doerfler WR, Ellis JT, Liang X, Ross MA, Wallace CT, Sperry JL, Lotze MT, Neal MD, Zeh HJ. Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. Bmc Cancer. 18: 678. PMID 29929491 DOI: 10.1186/S12885-018-4584-2  0.307
2018 Anunobi R, Boone BA, Cheh N, Tang D, Kang R, Loux T, Lotze MT, Zeh HJ. Extracellular DNA promotes colorectal tumor cell survival after cytotoxic chemotherapy. The Journal of Surgical Research. PMID 29605400 DOI: 10.1016/J.Jss.2018.02.042  0.379
2018 Kim HY, Wang X, Kang R, Tang D, Boone BA, Zeh HJ, Lotze MT, Edwards WB. RAGE-specific single chain Fv for PET imaging of pancreatic cancer. Plos One. 13: e0192821. PMID 29529089 DOI: 10.1371/Journal.Pone.0192821  0.34
2018 Appleman LJ, Logan TF, Normolle DP, Ernstoff MS, Parikh RA, McDermott DF, Monk P, Olencki T, Friedland D, Maranchie JK, Butterfield LH, Liang X, Lotze MT. Targeting autophagy and immunotherapy with hydroxychloroquine and interleukin 2 in patients with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group study. Journal of Clinical Oncology. 36: 106-106. DOI: 10.1200/Jco.2018.36.5_Suppl.106  0.315
2018 Appleman LJ, Normolle DP, Logan TF, Monk P, Olencki T, McDermott DF, Ernstoff MS, Maranchie JK, Parikh RA, Friedland D, Zeh H, Liang X, Butterfield LH, Lotze MT. Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study. Journal of Clinical Oncology. 36: 4573-4573. DOI: 10.1200/Jco.2018.36.15_Suppl.4573  0.31
2017 Song X, Zhu S, Xie Y, Liu J, Sun L, Zeng D, Wang P, Ma X, Kroemer G, Bartlett DL, Billiar TR, Lotze M, Zeh H, Kang R, Tang D. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Gastroenterology. PMID 29248440 DOI: 10.1053/J.Gastro.2017.12.004  0.356
2017 Chen R, Zhu S, Fan XG, Wang H, Lotze MT, Zeh HJ, Billiar TR, Kang R, Tang D. HMGB1 Controls Liver Cancer Initiation through YAP-dependent Aerobic Glycolysis. Hepatology (Baltimore, Md.). PMID 29149457 DOI: 10.1002/Hep.29663  0.339
2017 Xie Y, Zhu S, Song X, Sun X, Fan Y, Liu J, Zhong M, Yuan H, Zhang L, Billiar TR, Lotze MT, Zeh HJ, Kang R, Kroemer G, Tang D. The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. Cell Reports. 20: 1692-1704. PMID 28813679 DOI: 10.1016/J.Celrep.2017.07.055  0.376
2017 Xie Y, Zhu S, Zhong M, Yang M, Sun X, Liu J, Kroemer G, Lotze M, Zeh HJ, Kang R, Tang D. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma. Gastroenterology. PMID 28764929 DOI: 10.1053/J.Gastro.2017.07.036  0.368
2017 Kang R, Xie Y, Zhang Q, Hou W, Jiang Q, Zhu S, Liu J, Zeng D, Wang H, Bartlett DL, Billiar TR, Zeh HJ, Lotze MT, Tang D. Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Research. PMID 28374746 DOI: 10.1038/Cr.2017.51  0.332
2017 Dhupar R, Van Der Kraak L, Pennathur A, Schuchert MJ, Nason KS, Luketich JD, Lotze MT. Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor. The Annals of Thoracic Surgery. 103: 1340-1349. PMID 28359471 DOI: 10.1016/J.Athoracsur.2016.12.011  0.344
2017 Kaltenmeier CT, Vollmer LL, Vernetti LA, Caprio L, Davis K, Korotchenko VN, Day BW, Tsang M, Hulkower KI, Lotze MT, Vogt A. A tumor cell-selective inhibitor of mitogen-activated protein kinase phosphatases sensitizes breast cancer cells to lymphokine-activated killer cell activity. The Journal of Pharmacology and Experimental Therapeutics. PMID 28154014 DOI: 10.1124/Jpet.116.239756  0.355
2017 Zhu S, Zhang Q, Sun X, Zeh HJ, Lotze MT, Kang R, Tang D. HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells. Cancer Research. PMID 28130223 DOI: 10.1158/0008-5472.Can-16-1979  0.367
2017 Dhupar R, Lotze MT. PD-1 antagonist antibody treatment for patients with oesophageal squamous-cell carcinoma Ame Medical Journal. 2: 106-106. DOI: 10.21037/Amj.2017.08.03  0.354
2017 Sarnaik A, Kluger HM, Chesney JA, Sethuraman J, Veerapathran A, Simpson-Abelson M, Lotze MT, Larsen B, Fischkoff SA, Suzuki S, Wang L, Mirgoli M, Fardis M, Curti BD. Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy. Journal of Clinical Oncology. 35: 3045-3045. DOI: 10.1200/Jco.2017.35.15_Suppl.3045  0.334
2017 Simpson-Abelson MR, Mosychuk C, Fardis M, Lotze MT. Abstract 649: Emigrant pre-REP tumor infiltrating lymphocytes profoundly differ from remnant T-cells Immunology. 77: 649-649. DOI: 10.1158/1538-7445.Am2017-649  0.349
2016 Van Der Kraak L, Goel G, Ramanan K, Kaltenmeier C, Zhang L, Normolle DP, Freeman GJ, Tang D, Nason KS, Davison JM, Luketich JD, Dhupar R, Lotze MT. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. Journal For Immunotherapy of Cancer. 4: 65. PMID 27777774 DOI: 10.1186/S40425-016-0163-8  0.332
2016 Chen R, Xie Y, Zhong X, Fu Y, Huang Y, Zhen Y, Pan P, Wang H, Bartlett DL, Billiar TR, Lotze MT, Zeh Iii HJ, Fan XG, Tang D, Kang R. Novel chemokine-like activities of histones in tumor metastasis. Oncotarget. PMID 27623211 DOI: 10.18632/Oncotarget.11226  0.341
2016 Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, Hurwitz B, Relation T, Yu JG, Lee TJ, Lotze MT, Zhang J, Croce CM, Yu J, Caligiuri MA, et al. Bortezomib treatment sensitizes oncolytic HSV-1 treated tumors to NK cell immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27390350 DOI: 10.1158/1078-0432.Ccr-16-1003  0.382
2016 Goding SR, Yu S, Bailey LM, Lotze MT, Basse PH. Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells. Clinical Immunology (Orlando, Fla.). PMID 27377534 DOI: 10.1016/J.Clim.2016.06.013  0.412
2016 Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ, Kang R, Tang D. Autophagy Promotes Ferroptosis by Degradation of Ferritin. Autophagy. 0. PMID 27245739 DOI: 10.1080/15548627.2016.1187366  0.324
2016 Lotfi R, Kaltenmeier C, Lotze MT, Bergmann C. Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment. Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈Atologie. 43: 120-32. PMID 27226794 DOI: 10.1159/000444941  0.435
2016 Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro-Oncology. PMID 27116977 DOI: 10.1093/Neuonc/Now061  0.332
2016 Kang R, Chen R, Xie M, Cao L, Lotze MT, Tang D, Zeh HJ. The Receptor for Advanced Glycation End Products Activates the AIM2 Inflammasome in Acute Pancreatitis. Journal of Immunology (Baltimore, Md. : 1950). PMID 27045109 DOI: 10.4049/Jimmunol.1502340  0.367
2016 Xie Y, Song X, Sun X, Huang J, Zhong M, Lotze MT, Zeh HJ, Kang R, Tang D. Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochemical and Biophysical Research Communications. PMID 27037021 DOI: 10.1016/J.Bbrc.2016.03.052  0.306
2016 Goel G, Ramanan K, Kaltenmeier C, Zhang L, Freeman GJ, Normolle DP, Tang D, Lotze MT. Effect of 5-fluorouracil on membranous PD-L1 expression in colon cancer cells. Journal of Clinical Oncology. 34: 592-592. DOI: 10.1200/Jco.2016.34.4_Suppl.592  0.364
2015 Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT, Zeh HJ, Kang R, Tang D. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Molecular & Cellular Oncology. 2: e1054549. PMID 27308510 DOI: 10.1080/23723556.2015.1054549  0.337
2015 Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, ... ... Lotze MT, et al. Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology. 4: e998538. PMID 26137416 DOI: 10.1080/2162402X.2014.998538  0.333
2015 Boone BA, Orlichenko L, Schapiro NE, Loughran P, Gianfrate GC, Ellis JT, Singhi AD, Kang R, Tang D, Lotze MT, Zeh HJ. The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Cancer Gene Therapy. 22: 326-34. PMID 25908451 DOI: 10.1038/Cgt.2015.21  0.365
2015 Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, Singhi AD, Bao P, Bartlett DL, Liotta LA, Espina V, Loughran P, Lotze MT, Zeh HJ. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Annals of Surgical Oncology. PMID 25905586 DOI: 10.1245/S10434-015-4566-4  0.358
2015 Shakir M, Tang D, Zeh HJ, Tang SW, Anderson CJ, Bahary N, Lotze MT. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow. Pancreas. 44: 528-34. PMID 25872129 DOI: 10.1097/Mpa.0000000000000298  0.772
2015 Chen R, Fu S, Fan XG, Lotze MT, Zeh HJ, Tang D, Kang R. Nuclear DAMP complex-mediated RAGE-dependent macrophage cell death. Biochemical and Biophysical Research Communications. 458: 650-5. PMID 25684181 DOI: 10.1016/J.Bbrc.2015.01.159  0.381
2015 Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian D, Lotze M, Tang D, Tsung A. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. Journal of Hepatology. 63: 114-21. PMID 25681553 DOI: 10.1016/J.Jhep.2015.02.009  0.361
2015 Zhu X, Messer JS, Wang Y, Lin F, Cham CM, Chang J, Billiar TR, Lotze MT, Boone DL, Chang EB. Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. The Journal of Clinical Investigation. 125: 1098-110. PMID 25642769 DOI: 10.1172/Jci76344  0.324
2015 Sehgal AR, Konig H, Johnson DE, Tang D, Amaravadi RK, Boyiadzis M, Lotze MT. You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia. 29: 517-25. PMID 25541151 DOI: 10.1038/Leu.2014.349  0.372
2015 Liang X, Wang W, Li G, Zhang X, Jankovic V, Herzberg U, Hofgartner W, Lotze MT. Efficacy of adoptive transfer of expanded fetal liver-derived precursor syngeneic and allogeneic murine NK cells against solid tumors Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P30  0.366
2015 Li G, Vernon PJ, Houten Bv, Liang X, Lotze MT. Abstract B08: HMGB1 regulates natural killer (NK) cell metabolism and cross-talk with dendritic cells (DCs) Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-B08  0.786
2015 Zhang X, Rao A, Deibert C, Sette P, Kim J, Lotze M, Grandi P, Amankulor N. Imps-45Idh Mutant Gliomas Escape Natural Killer Cell Immune Surveillance Through Downregulation Of Nkg2D Ligands Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov217.44  0.362
2014 Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, ... ... Lotze MT, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519 DOI: 10.18632/Oncotarget.2998  0.354
2014 Huang J, Xie Y, Sun X, Zeh HJ, Kang R, Lotze MT, Tang D. DAMPs, ageing, and cancer: The 'DAMP Hypothesis' Ageing Research Reviews. PMID 25446804 DOI: 10.1016/J.Arr.2014.10.004  0.302
2014 Kang R, Hou W, Zhang Q, Chen R, Lee YJ, Bartlett DL, Lotze MT, Tang D, Zeh HJ. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Cell Death & Disease. 5: e1480. PMID 25341034 DOI: 10.1038/Cddis.2014.445  0.405
2014 Kang R, Lotze MT, Zeh HJ, Billiar TR, Tang D. Cell death and DAMPs in acute pancreatitis. Molecular Medicine (Cambridge, Mass.). 20: 466-77. PMID 25105302 DOI: 10.2119/Molmed.2014.00117  0.338
2014 Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, Huang J, Yu Y, Fan XG, Yan Z, Sun X, Wang H, Wang Q, Tsung A, Billiar TR, ... ... Lotze MT, et al. HMGB1 in health and disease. Molecular Aspects of Medicine. 40: 1-116. PMID 25010388 DOI: 10.1016/J.Mam.2014.05.001  0.361
2014 Eisenbacher JL, Schrezenmeier H, Jahrsdörfer B, Kaltenmeier C, Rojewski MT, Yildiz T, Beyer T, Erle A, Wiegmann DS, Grassl S, Hang R, Körper S, Wiesneth M, Lotze MT, Lotfi R. S100A4 and uric acid promote mesenchymal stromal cell induction of IL-10+/IDO+ lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 192: 6102-10. PMID 24795458 DOI: 10.4049/Jimmunol.1303144  0.414
2014 Kang R, Zhang Q, Hou W, Yan Z, Chen R, Bonaroti J, Bansal P, Billiar TR, Tsung A, Wang Q, Bartlett DL, Whitcomb DC, Chang EB, Zhu X, Wang H, ... ... Lotze MT, et al. Intracellular Hmgb1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology. 146: 1097-107. PMID 24361123 DOI: 10.1053/J.Gastro.2013.12.015  0.304
2014 Boone BA, Lotze MT. Targeting damage-associated molecular pattern molecules (DAMPs) and DAMP receptors in melanoma Methods in Molecular Biology. 1102: 537-552. PMID 24258998 DOI: 10.1007/978-1-62703-727-3_29  0.38
2014 Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, Billiar TR, Wang H, Van Houten B, Lotze MT, Zeh HJ. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene. 33: 567-77. PMID 23318458 DOI: 10.1038/Onc.2012.631  0.381
2014 Lotze MT, Boone BA, Zureikat AH, Bahary N, Lehman D, Liotta LA, Zeh HJ. Phase I/II trial of autophagy inhibition in combination with neoadjuvant gemcitabine in patients with high-risk pancreatic adenocarcinoma: Safety, clinical response, and correlative studies. Journal of Clinical Oncology. 32: 218-218. DOI: 10.1200/Jco.2014.32.3_Suppl.218  0.31
2014 Wang W, Vernon P, Li G, Sampath P, Stephen T, Liang X, Lotze M. Depletion of high mobility group box 1(HMGB1) in dendritic cells (DCs) suppresses tumorigenesis and promotes viral clearance Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P64  0.784
2014 Kang R, Zhang Q, Hou W, Chen R, Lotze M, Zeh H, Tang D. Abstract 2031: HMGB1 regulates pancreatic cancer initiation and pogression Cancer Research. 74: 2031-2031. DOI: 10.1158/1538-7445.Am2014-2031  0.34
2014 Brancho M, Chang Y, Zhang X, Okada H, Li A, Grandi P, Lotze M, Amankulor N. Ib-03Idh Mutant Gliomas Are Resistant To Natural Killer Cell-Mediated Cytolysis Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou257.3  0.401
2014 Boone B, Schapiro N, Neal M, Ellis J, Lotze M, Zeh H. Neutrophil Extracellular Traps (NETs) are Upregulated in Pancreatic Cancer as a Result of Autophagy and Promote Hypercoagulability Journal of Surgical Research. 186: 638. DOI: 10.1016/J.Jss.2013.11.657  0.326
2013 Hou W, Zhang Q, Yan Z, Chen R, Zeh Iii HJ, Kang R, Lotze MT, Tang D. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death & Disease. 4: e966. PMID 24336086 DOI: 10.1038/cddis.2013.493  0.323
2013 Rubartelli A, Lotze MT, Latz E, Manfredi A. Mechanisms of sterile inflammation. Frontiers in Immunology. 4: 398. PMID 24319446 DOI: 10.3389/Fimmu.2013.00398  0.36
2013 Li G, Tang D, Lotze MT. Ménage à Trois in stress: DAMPs, redox and autophagy Seminars in Cancer Biology. 23: 380-390. PMID 23994764 DOI: 10.1016/J.Semcancer.2013.08.002  0.322
2013 Lotze MT, Maranchie J, Appleman L. Inhibiting autophagy: a novel approach for the treatment of renal cell carcinoma. Cancer Journal (Sudbury, Mass.). 19: 341-7. PMID 23867516 DOI: 10.1097/Ppo.0B013E31829Da0D6  0.344
2013 Lu Y, Zhang Z, Yan Z, Chen L, Deng W, Lotze M, Wang Z, Lin X, Li LY. Recombinant GnRH-p53 protein sensitizes breast cancer cells to 5-fluorouracil-induced apoptosis in vitro and in vivo. Apoptosis : An International Journal On Programmed Cell Death. 18: 1214-23. PMID 23801079 DOI: 10.1007/S10495-013-0863-1  0.331
2013 Tang S, Bonaroti J, Unlu S, Liang X, Tang D, Zeh HJ, Lotze MT. Sweating the small stuff: MicroRNAs and genetic changes define pancreatic cancer Pancreas. 42: 740-759. PMID 23774697 DOI: 10.1097/Mpa.0B013E3182854Ab0  0.765
2013 Vernon PJ, Zeh Iii HJ, Lotze MT. The myeloid response to pancreatic carcinogenesis is regulated by the receptor for advanced glycation end-products. Oncoimmunology. 2: e24184. PMID 23762800 DOI: 10.4161/Onci.24184  0.77
2013 Criscimanna A, Duan LJ, Rhodes JA, Fendrich V, Wickline E, Hartman DJ, Monga SP, Lotze MT, Gittes GK, Fong GH, Esni F. PanIN-specific regulation of Wnt signaling by HIF2α during early pancreatic tumorigenesis. Cancer Research. 73: 4781-90. PMID 23749643 DOI: 10.1158/0008-5472.Can-13-0566  0.328
2013 Kang R, Zhang Q, Zeh HJ, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4046-57. PMID 23723299 DOI: 10.1158/1078-0432.Ccr-13-0495  0.42
2013 Li G, Liang X, Lotze MT. HMGB1: The Central Cytokine for All Lymphoid Cells. Frontiers in Immunology. 4: 68. PMID 23519706 DOI: 10.3389/Fimmu.2013.00068  0.41
2013 Kim S, Kim SY, Pribis JP, Lotze M, Mollen KP, Shapiro R, Loughran P, Scott MJ, Billiar TR. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Molecular Medicine (Cambridge, Mass.). 19: 88-98. PMID 23508573 DOI: 10.2119/Molmed.2012.00306  0.303
2013 Zhang Q, Kang R, Zeh HJ, Lotze MT, Tang D. DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death. Autophagy. 9: 451-8. PMID 23388380 DOI: 10.4161/Auto.23691  0.314
2013 Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT. Life after death: targeting high mobility group box 1 in emergent cancer therapies. American Journal of Cancer Research. 3: 1-20. PMID 23359863  0.328
2013 Vernon PJ, Loux TJ, Schapiro NE, Kang R, Muthuswamy R, Kalinski P, Tang D, Lotze MT, Zeh HJ. The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. Journal of Immunology (Baltimore, Md. : 1950). 190: 1372-9. PMID 23269246 DOI: 10.4049/Jimmunol.1201151  0.787
2013 Kang R, Tang D, Lotze MT, Zeh Iii HJ. Autophagy is required for IL-2-mediated fibroblast growth. Experimental Cell Research. 319: 556-65. PMID 23195496 DOI: 10.1016/J.Yexcr.2012.11.012  0.37
2013 Vernon PJ, Zeh HJ, Lotze MT. The myeloid response to pancreatic carcinogenesis is regulated by the receptor for advanced glycation end-products Oncoimmunology. 2. DOI: 10.4161/onci.24184  0.74
2013 Li G, Liang X, Lotze M. NK cell HMGB1 mediates IL-2-induced “systemic autophagic” toxicity Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P123  0.338
2012 Tang D, Billiar TR, Lotze MT. A Janus tale of two active high mobility group box 1 (HMGB1) redox states Molecular Medicine. 18: 1360-1362. PMID 23073660 DOI: 10.2119/Molmed.2012.00314  0.366
2012 Tang S, Lotze MT. The power of negative thinking: Which cells limit tumor immunity? Clinical Cancer Research. 18: 5157-5159. PMID 22912390 DOI: 10.1158/1078-0432.Ccr-12-2418  0.786
2012 Tang D, Lotze MT. Tumor immunity times out: TIM-3 and HMGB1 Nature Immunology. 13: 808-810. PMID 22910384 DOI: 10.1038/Ni.2396  0.374
2012 Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunological Reviews. 249: 158-75. PMID 22889221 DOI: 10.1111/J.1600-065X.2012.01146.X  0.352
2012 Ferris RL, Lotze MT, Leong SPL, Hoon DSB, Morton DL. Lymphatics, lymph nodes and the immune system: Barriers and gateways for cancer spread Clinical and Experimental Metastasis. 29: 729-736. PMID 22851005 DOI: 10.1007/S10585-012-9520-2  0.359
2012 Unlu S, Tang S, Wang E, Wang En, Martinez I, Tang D, Bianchi ME, Zeh HJ, Lotze MT. Damage associated molecular pattern molecule-induced microRNAs (DAMPmiRs) in human peripheral blood mononuclear cells. Plos One. 7: e38899. PMID 22745684 DOI: 10.1371/Journal.Pone.0038899  0.759
2012 Kang R, Tang D, Lotze MT, Zeh HJ. AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy. 8: 989-91. PMID 22722139 DOI: 10.4161/Auto.20258  0.422
2012 Lotze MT, Buchser WJ, Liang X. Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy. 8: 1264-6. PMID 22660171 DOI: 10.4161/Auto.20752  0.457
2012 Livesey KM, Kang R, Zeh HJ, Lotze MT, Tang D. Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy. 8: 846-8. PMID 22647615 DOI: 10.4161/Auto.19891  0.381
2012 Yu Y, Cao L, Yang L, Kang R, Lotze M, Tang D. microRNA 30A promotes autophagy in response to cancer therapy. Autophagy. 8: 853-5. PMID 22617440 DOI: 10.4161/Auto.20053  0.367
2012 Kang R, Loux T, Tang D, Schapiro NE, Vernon P, Livesey KM, Krasinskas A, Lotze MT, Zeh HJ. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proceedings of the National Academy of Sciences of the United States of America. 109: 7031-6. PMID 22509024 DOI: 10.1073/Pnas.1113865109  0.773
2012 Buchser WJ, Laskow TC, Pavlik PJ, Lin HM, Lotze MT. Cell-mediated autophagy promotes cancer cell survival. Cancer Research. 72: 2970-9. PMID 22505650 DOI: 10.1158/0008-5472.Can-11-3396  0.434
2012 Liang X, De Vera ME, Buchser WJ, Romo de Vivar Chavez A, Loughran P, Beer Stolz D, Basse P, Wang T, Van Houten B, Zeh HJ, Lotze MT. Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Research. 72: 2791-801. PMID 22472122 DOI: 10.1158/0008-5472.Can-12-0320  0.414
2012 Weiner LM, Lotze MT. Tumor-cell death, autophagy, and immunity. The New England Journal of Medicine. 366: 1156-8. PMID 22435376 DOI: 10.1056/Nejmcibr1114526  0.392
2012 Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, Zhang L, Manfredi JJ, Zeh HJ, Li L, Lotze MT, Tang D. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Research. 72: 1996-2005. PMID 22345153 DOI: 10.1158/0008-5472.Can-11-2291  0.768
2012 Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT, Tsung A. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (Baltimore, Md.). 55: 1863-75. PMID 22234969 DOI: 10.1002/Hep.25572  0.318
2012 Kang R, Tang D, Schapiro NE, Lotze MT, Zeh HJ. Abstract B96: The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-B96  0.427
2011 Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, ... ... Lotze MT, et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 9: 214. PMID 22168571 DOI: 10.1186/1479-5876-9-214  0.315
2011 Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, Kalinski P. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 270-8. PMID 21389871 DOI: 10.1097/Cji.0B013E31820B370B  0.398
2011 Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E. Principles and current strategies for targeting autophagy for cancer treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 654-66. PMID 21325294 DOI: 10.1158/1078-0432.Ccr-10-2634  0.347
2011 Kang R, Tang D, Lotze MT, Zeh HJ. RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy. 7: 442-4. PMID 21317562 DOI: 10.4161/Auto.7.4.14681  0.352
2011 Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death and Differentiation. 18: 571-80. PMID 21311563 DOI: 10.1038/Cdd.2010.191  0.313
2011 Tang D, Lotze MT, Kang R, Zeh HJ. Apoptosis promotes early tumorigenesis. Oncogene. 30: 1851-4. PMID 21151175 DOI: 10.1038/Onc.2010.573  0.305
2011 Kang R, Tang D, Livesey KM, Schapiro NE, Lotze MT, Zeh HJ. The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. Antioxidants & Redox Signaling. 15: 2175-84. PMID 21126167 DOI: 10.1089/Ars.2010.3378  0.358
2011 Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Lotze MT, Tang D, Cao L. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia. 25: 23-31. PMID 20927132 DOI: 10.1038/Leu.2010.225  0.359
2011 Loux T, Schapiro N, Kang R, Tang D, Lotze M, Zeh H. Pancreatic Cancer Induces Systemic Autophagy Journal of Surgical Research. 165: 336. DOI: 10.1016/J.Jss.2010.11.207  0.301
2010 John E, Laskow TC, Buchser WJ, Pitt BR, Basse PH, Butterfield LH, Kalinski P, Lotze MT. Zinc in innate and adaptive tumor immunity. Journal of Translational Medicine. 8: 118. PMID 21087493 DOI: 10.1186/1479-5876-8-118  0.405
2010 Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ, Lotze MT. Endogenous HMGB1 regulates autophagy. The Journal of Cell Biology. 190: 881-92. PMID 20819940 DOI: 10.1083/Jcb.200911078  0.321
2010 Lesinski GB, Carson WE, Repasky EA, Wei WZ, Kalinski P, Lotze MT, June CH, Petros W, Muthusamy N, Olencki T. Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 659-62. PMID 20664361 DOI: 10.1097/Cji.0B013E3181Eccbf7  0.306
2010 Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, Zeh HJ, Lotze MT. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 29: 5299-310. PMID 20622903 DOI: 10.1038/Onc.2010.261  0.369
2010 Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI, Bianchi ME, Carbone M. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proceedings of the National Academy of Sciences of the United States of America. 107: 12611-6. PMID 20616036 DOI: 10.1073/Pnas.1006542107  0.343
2010 Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, ... ... Lotze MT, et al. Cancer and inflammation: promise for biologic therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 335-51. PMID 20386472 DOI: 10.1097/Cji.0B013E3181D32E74  0.399
2010 Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, Martinson J, Lotze MT, Marincola FM, Wang E, Fujita M, Okada H. miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. Journal of Translational Medicine. 8: 17. PMID 20167088 DOI: 10.1186/1479-5876-8-17  0.334
2010 Tang D, Kang R, Zeh HJ, Lotze MT. High-mobility group box 1 and cancer. Biochimica Et Biophysica Acta. 1799: 131-40. PMID 20123075 DOI: 10.1016/J.Bbagrm.2009.11.014  0.352
2010 Liang X, Chavaz ARdV, Schapiro NE, Thorne SH, Wang T, Houten Bv, Lotze MT, Vera Md. Abstract 60: Altering tumor cell metabolism may contribute to the antitumor activity of ethyl pyruvate Cellular and Molecular Biology. 70: 60-60. DOI: 10.1158/1538-7445.Am10-60  0.339
2010 Tang D, Kang R, Zeh HJ, Lotze MT. Abstract 4854: Inhibition of high-mobility group box 1 protein (HMGB1) release sensitizes cancer cells to chemotherapy Cancer Research. 70: 4854-4854. DOI: 10.1158/1538-7445.Am10-4854  0.422
2010 Kang R, Tang D, Lotze MT, Zeh HJ. Abstract 4674: Receptor for advanced glycation endproducts (RAGE) regulates ß-catenin function and chemosensitivity in pancreatic cancer cells Cancer Research. 70: 4674-4674. DOI: 10.1158/1538-7445.Am10-4674  0.327
2010 Loux T, Schapiro N, Kang R, Tang D, Lotze M, Zeh H. Inhibition of Autophagy by Chloroquine Enhances Chemotherapy in an Orthotopic Murine Model of Pancreatic Cancer Journal of Surgical Research. 158: 393-394. DOI: 10.1016/J.Jss.2009.11.617  0.322
2010 Chavez ARdV, Liang X, Lotze MT, Vera MED. Expression and Effects of IL-33 and Its Receptor in a Murine Pancreatic Cell Line Journal of Surgical Research. 158: 197-198. DOI: 10.1016/J.Jss.2009.11.084  0.349
2010 Liang X, Romo de Vivar A, Lotze M, de Vera M. Ethyl Pyruvate Alters Tumor Cell Metabolism and Inhibits Hepatic Tumor Growth Journal of Surgical Research. 158: 197. DOI: 10.1016/J.Jss.2009.11.082  0.331
2009 Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT. Pharmacologic administration of interleukin-2. Annals of the New York Academy of Sciences. 1182: 14-27. PMID 20074271 DOI: 10.1111/J.1749-6632.2009.05160.X  0.416
2009 Lotfi R, Herzog GI, DeMarco RA, Beer-Stolz D, Lee JJ, Rubartelli A, Schrezenmeier H, Lotze MT. Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells Journal of Immunology. 183: 5023-5031. PMID 19794066 DOI: 10.4049/Jimmunol.0900504  0.358
2009 Liang X, Chavez AR, Schapiro NE, Loughran P, Thorne SH, Amoscato AA, Zeh HJ, Beer-Stolz D, Lotze MT, de Vera ME. Ethyl pyruvate administration inhibits hepatic tumor growth. Journal of Leukocyte Biology. 86: 599-607. PMID 19584311 DOI: 10.1189/Jlb.0908578  0.403
2009 Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, ... ... Lotze MT, et al. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. Journal of Translational Medicine. 7: 45. PMID 19534815 DOI: 10.1186/1479-5876-7-45  0.369
2009 Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, Khan SA, Sobol RW, Okada H. Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proceedings of the National Academy of Sciences of the United States of America. 106: 10746-51. PMID 19520829 DOI: 10.1073/Pnas.0811817106  0.372
2009 Cardinal J, Pan P, Dhupar R, Ross M, Nakao A, Lotze M, Billiar T, Geller D, Tsung A. Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology (Baltimore, Md.). 50: 565-74. PMID 19492424 DOI: 10.1002/Hep.23021  0.326
2009 Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. Journal of Translational Medicine. 7: 17. PMID 19292913 DOI: 10.1186/1479-5876-7-17  0.357
2009 Lotfi R, Schrezenmeier H, Lotze MT. Immunotherapy for cancer: Promoting innate immunity Frontiers in Bioscience. 14: 818-832. PMID 19273102 DOI: 10.2741/3280  0.407
2009 Tang D, Kang R, Xiao W, Zhang H, Lotze MT, Wang H, Xiao X. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. American Journal of Respiratory Cell and Molecular Biology. 41: 651-60. PMID 19265175 DOI: 10.1165/Rcmb.2008-0119Oc  0.314
2009 Romo de Vivar Chavez A, de Vera ME, Liang X, Lotze MT. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma Medical Oncology (Northwood, London, England). 26: 3-12. PMID 19148593 DOI: 10.1007/S12032-008-9162-Z  0.427
2009 Anunobi R, Lotze MT, Zeh HJ. QS358. Toll Like Receptor-9 Signaling in Tumor Cells Promotes Survival Following Cytotoxic Insult Journal of Surgical Research. 151: 298. DOI: 10.1016/J.Jss.2008.11.667  0.37
2008 Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT. Focus on FOCIS: Interleukin 2 treatment associated autoimmunity Clinical Immunology. 127: 123-129. PMID 18405863 DOI: 10.1016/J.Clim.2008.02.011  0.412
2008 Vakkila J, Demarco RA, Lotze MT. Coordinate NF-κB and STAT1 activation promotes development of myeloid type 1 dendritic cells Scandinavian Journal of Immunology. 67: 260-269. PMID 18261039 DOI: 10.1111/J.1365-3083.2007.02068.X  0.343
2008 Östberg T, Wähämaa H, Palmblad K, Ito N, Stridh P, Shoshan M, Lotze MT, Harris HE, Andersson U. Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis Arthritis Research and Therapy. 10. PMID 18179697 DOI: 10.1186/Ar2347  0.308
2008 Lotfi R, Lotze MT. Eosinophils induce DC maturation, regulating immunity Journal of Leukocyte Biology. 83: 456-460. PMID 17991762 DOI: 10.1189/Jlb.0607366  0.386
2008 Liang X, Farkas AM, Lotze MT, DeVera ME. The Damage Associated Molecular Pattern Molecule [Damp] Hmgb1 Enhance Tlr And Rage Expression On Hepatic Stellate Cell (Hsc), Stimulates Activation And Proliferation: 1659 Transplantation. 86: 550. DOI: 10.1097/01.Tp.0000331164.09755.6C  0.308
2008 Kang R, Tang D, Schapiro N, Lotze M, Zeh H. Su.70. The Receptor for Advanced Glycation End Products (RAGE) is Associated with the Tumor Cell Response to Stress Clinical Immunology. 127: S147. DOI: 10.1016/J.Clim.2008.03.421  0.351
2007 Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends in Immunology. 28: 429-36. PMID 17845865 DOI: 10.1016/J.It.2007.08.004  0.324
2007 Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4677-85. PMID 17699845 DOI: 10.1158/1078-0432.Ccr-07-0776  0.367
2007 Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 596-606. PMID 17667523 DOI: 10.1097/Cji.0B013E31804Efc76  0.443
2007 Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT. Masquerader: high mobility group box-1 and cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2836-48. PMID 17504981 DOI: 10.1158/1078-0432.Ccr-06-1953  0.397
2007 Lotfi R, Lee JJ, Lotze MT. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 16-28. PMID 17198080 DOI: 10.1097/01.Cji.0000211324.53396.F6  0.393
2007 Tsung A, Zheng N, Jeyabalan G, Izuishi K, Klune JR, Geller DA, Lotze MT, Lu L, Billiar TR. Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. Journal of Leukocyte Biology. 81: 119-28. PMID 17062605 DOI: 10.1189/Jlb.0706468  0.313
2007 Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P, Stolz DB, Zeh HJ, Lotze MT. Cytolytic cells induce HMGB1 release from melanoma cell lines. Journal of Leukocyte Biology. 81: 75-83. PMID 16968820 DOI: 10.1189/Jlb.0306169  0.41
2006 Popovic PJ, DeMarco R, Lotze MT, Winikoff SE, Bartlett DL, Krieg AM, Guo ZS, Brown CK, Tracey KJ, Zeh HJ. High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. Journal of Immunology (Baltimore, Md. : 1950). 177: 8701-7. PMID 17142771 DOI: 10.4049/Jimmunol.177.12.8701  0.413
2006 Wang Y, Zheng N, Lu Z, Wu W, Wang L, Nakao A, Lotze MT, Langer CE, Fung JJ, Qian S, Lu L. In vivo expansion of two distinct dendritic cells in mouse livers and its impact on liver immune regulation. Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society. 12: 1850-61. PMID 17133587 DOI: 10.1002/Lt.20919  0.357
2006 Montag DT, Lotze MT. Rapid flow cytometric measurement of cytokine-induced phosphorylation pathways [CIPP] in human peripheral blood leukocytes Clinical Immunology. 121: 215-226. PMID 16959540 DOI: 10.1016/J.Clim.2006.06.013  0.342
2006 Montag DT, Lotze MT. Successful simultaneous measurement of cell membrane and cytokine induced phosphorylation pathways [CIPP] in human peripheral blood mononuclear cells. Journal of Immunological Methods. 313: 48-60. PMID 16716344 DOI: 10.1016/J.Jim.2006.03.014  0.333
2006 Vakkila J, Jaffe R, Michelow M, Lotze MT. Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2049-54. PMID 16609014 DOI: 10.1158/1078-0432.Ccr-05-1824  0.33
2006 D'Aiuto L, De Marco R, Edward N, Rizzo A, Chaillet JR, Montecalvo A, Lotze MT, Gambotto A. Evidence of the capability of the CMV enhancer to activate in trans gene expression in mammalian cells. Dna and Cell Biology. 25: 171-80. PMID 16569196 DOI: 10.1089/Dna.2006.25.171  0.307
2006 Eto M, Bennouna J, Hunter OC, Lotze MT, Amoscato AA. Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells. International Journal of Urology : Official Journal of the Japanese Urological Association. 13: 148-56. PMID 16563140 DOI: 10.1111/J.1442-2042.2006.01249.X  0.306
2005 Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, Winans MT, Lee K, Moser A, Bartlett D, Lotze MT, Siegfried JM, Whitcomb D, Papacristou G, Slivka A, et al. Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomarkers : Section a of Disease Markers. 1: 259-69. PMID 17192050 DOI: 10.3233/Cbm-2005-1601  0.319
2005 Fujii S, Nishimura MI, Lotze MT. Regulatory balance between the immune response of tumor antigen-specific T-cell receptor gene-transduced CD8 T cells and the suppressive effects of tolerogenic dendritic cells. Cancer Science. 96: 897-902. PMID 16367910 DOI: 10.1111/J.1349-7006.2005.00124.X  0.419
2005 Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, Yin X, Yang S, Zeh HJ, Moss B, Lotze MT, Bartlett DL. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Research. 65: 9991-8. PMID 16267024 DOI: 10.1158/0008-5472.Can-05-1630  0.376
2005 Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. Journal of Immunology (Baltimore, Md. : 1950). 175: 6177-89. PMID 16237115 DOI: 10.4049/Jimmunol.175.9.6177  0.36
2005 Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opinion On Biological Therapy. 5: 1303-15. PMID 16197336 DOI: 10.1517/14712598.5.10.1303  0.412
2005 Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal Nature Reviews Immunology. 5: 331-342. PMID 15803152 DOI: 10.1038/Nri1594  0.321
2005 Lotze MT, Wang E, Marincola FM, Hanna N, Bugelski PJ, Burns CA, Coukos G, Damle N, Godfrey TE, Howell WM, Panelli MC, Perricone MA, Petricoin EF, Sauter G, Scheibenbogen C, et al. Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 79-119. PMID 15725954 DOI: 10.1097/01.Cji.0000154251.20125.2E  0.385
2005 Vakkila J, Lotze MT, Riga C, Jaffe R. A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 8: 43-51. PMID 15717117 DOI: 10.1007/S10024-004-5045-2  0.303
2005 Zeh HJ, Lotze MT. Addicted to death: Invasive cancer and the immune response to unscheduled cell death Journal of Immunotherapy. 28: 1-9. PMID 15614039 DOI: 10.1097/00002371-200501000-00001  0.413
2005 Demarco RA, Fink MP, Lotze MT. Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1 Molecular Immunology. 42: 433-444. PMID 15607795 DOI: 10.1016/J.Molimm.2004.07.023  0.429
2005 Vakkila J, Jaffe R, Michelow M, Lotze MT. Pediatric Cancers are Infiltrated Predominantly by Macrophages and Dendritic Cells are Lacking Journal of Immunotherapy. 28: 637. DOI: 10.1097/01.Cji.0000191027.28663.51  0.351
2005 Lotfi R, DeMarco RA, Lotze MT. Eosinophil Survival and Chemotaxis Are Enhanced by HMGB1: Implications for the Immunotherapy of Cancer Journal of Immunotherapy. 28: 624. DOI: 10.1097/01.Cji.0000190983.54212.70  0.306
2005 Ito N, DeMarco RA, Lotze MT. Flow Cytometric Assessment of HMGB1 and Histone H1 Release During Tumor Cell Death Following In Vitro Treatment Journal of Immunotherapy. 28: 621. DOI: 10.1097/01.Cji.0000190976.77975.48  0.308
2005 Langer C, Chen Y, Liang X, Zheng N, Lotze M, Geller D, Qian S, Lu L, Vera Md. Human CD11c+ intrahepatic dendritic cells (IHDC) are immunogenic by nature Journal of the American College of Surgeons. 201. DOI: 10.1016/J.Jamcollsurg.2005.06.218  0.316
2004 Vakkila J, DeMarco RA, Lotze MT. Imaging analysis of STAT1 and NF-κB translocation in dendritic cells at the single cell level Journal of Immunological Methods. 294: 123-134. PMID 15604022 DOI: 10.1016/J.Jim.2004.09.007  0.358
2004 Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth Nature Reviews Immunology. 4: 641-648. PMID 15286730 DOI: 10.1038/Nri1415  0.383
2004 Agha-Mohammadi S, O'Malley M, Etemad A, Wang Z, Xiao X, Lotze MT. Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. The Journal of Gene Medicine. 6: 817-28. PMID 15241789 DOI: 10.1002/Jgm.566  0.314
2004 Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunology Letters. 93: 39-43. PMID 15134897 DOI: 10.1016/J.Imlet.2004.01.014  0.327
2004 Lotze MT, Papamichail M. A primer on cancer immunology and immunotherapy Cancer Immunology, Immunotherapy. 53: 135-138. PMID 14740175 DOI: 10.1007/S00262-003-0467-7  0.405
2004 Lotze MT, Rees RC. Identifying biomarkers and surrogates of tumors (cancer biometrics): correlation with immunotherapies and immune cells. Cancer Immunology, Immunotherapy : Cii. 53: 256-61. PMID 14735318 DOI: 10.1007/S00262-003-0487-3  0.393
2003 Kitagawa T, Iwazawa T, Robbins PD, Lotze MT, Tahara H. Advantages and limitations of particle-mediated transfection (gene gun) in cancer immuno-gene therapy using IL-10, IL-12 or B7-1 in murine tumor models Journal of Gene Medicine. 5: 958-965. PMID 14601133 DOI: 10.1002/Jgm.441  0.381
2003 Eto M, Bennouna J, Hunter OC, Hershberger PA, Kanto T, Johnson CS, Lotze MT, Amoscato AA. C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. The Prostate. 57: 66-79. PMID 12886525 DOI: 10.1002/Pros.10275  0.308
2003 Son YI, Dallal RM, Lotze MT. Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response Journal of Immunotherapy. 26: 234-240. PMID 12806277 DOI: 10.1097/00002371-200305000-00007  0.389
2003 Nishioka Y, Wen H, Mitani K, Robbins PD, Lotze MT, Sone S, Tahara H. Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide. Journal of Leukocyte Biology. 73: 621-9. PMID 12714577 DOI: 10.1189/Jlb.0402205  0.352
2003 Redlinger RE, Mailliard RB, Lotze MT, Barksdale EM. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. Journal of Pediatric Surgery. 38: 301-7; discussion 30. PMID 12632339 DOI: 10.1053/Jpsu.2003.50098  0.32
2003 Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto A. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity Journal of Immunology. 170: 107-113. PMID 12496389 DOI: 10.4049/Jimmunol.170.1.107  0.351
2003 Hashimoto W, Tanaka F, Robbins PD, Taniguchi M, Okamura H, Lotze MT, Tahara H. Natural killer, but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL-18 International Journal of Cancer. 103: 508-513. PMID 12478667 DOI: 10.1002/Ijc.10844  0.409
2003 Numasaki M, Fukushi JI, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth Blood. 101: 2620-2627. PMID 12411307 DOI: 10.1182/Blood-2002-05-1461  0.355
2002 Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Herberman RB, Lotze MT, Shurin MR. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice Journal of Experimental Therapeutics and Oncology. 2: 337-349. PMID 12440225 DOI: 10.1046/J.1359-4117.2002.01050.X  0.409
2002 Tanaka F, Hashimoto W, Robbins PD, Lotze MT, Tahara H. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18 Gene Therapy. 9: 1480-1486. PMID 12378411 DOI: 10.1038/Sj.Gt.3301827  0.394
2002 Kumar S, Hanning CR, Brigham-Burke MR, Rieman DJ, Lehr R, Khandekar S, Kirkpatrick RB, Scott GF, Lee JC, Lynch FJ, Gao W, Gambotto A, Lotze MT. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine. 18: 61-71. PMID 12096920 DOI: 10.1006/Cyto.2002.0873  0.312
2002 Jonak ZL, Trulli S, Maier C, McCabe FL, Kirkpatrick R, Johanson K, Ho YS, Elefante L, Chen YJ, Herzyk D, Lotze MT, Johnson RK. High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 25: S20-7. PMID 12048347 DOI: 10.1097/00002371-200203001-00004  0.344
2002 Lotze MT, Tahara H, Okamura H. Interleukin-18 as a novel, distinct, and distant member of the interleukin-1 family promoting development of the adaptive immune response: The interleukin-18 issue of the Journal of Immunotherapy Journal of Immunotherapy. 25. PMID 12048344 DOI: 10.1097/00002371-200203001-00001  0.301
2002 Shimamura H, Cumberland R, Hiroishi K, Watkins SC, Lotze MT, Baar J. Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide. Journal of Immunotherapy (Hagerstown, Md. : 1997). 25: 226-34. PMID 12000864 DOI: 10.1097/00002371-200205000-00005  0.401
2002 Dallal RM, Christakos P, Lee K, Egawa S, Son YI, Lotze MT. Paucity of dendritic cells in pancreatic cancer. Surgery. 131: 135-8. PMID 11854690 DOI: 10.1067/Msy.2002.119937  0.389
2002 Mailliard RB, Egawa S, Cai Q, Kalinska A, Bykovskaya SN, Lotze MT, Kapsenberg ML, Storkus WJ, Kalinski P. Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. The Journal of Experimental Medicine. 195: 473-83. PMID 11854360 DOI: 10.1084/Jem.20011662  0.321
2002 Odoux C, Albers A, Amoscato AA, Lotze MT, Wong MK. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. International Journal of Cancer. 97: 458-65. PMID 11802207 DOI: 10.1002/Ijc.1640  0.339
2002 Dutcher J, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M. Phase II trial of interleukin 2, interferon α, and 5-fluorouracil in metastatic renal cell cancer Urologic Oncology-Seminars and Original Investigations. 7: 83-84. DOI: 10.1016/S1078-1439(01)00163-6  0.311
2001 Son YI, Mailliard RB, Watkins SC, Lotze MT. Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti-tumor effects when combined with interleukin-2. The Laryngoscope. 111: 1472-8. PMID 11568586 DOI: 10.1097/00005537-200108000-00026  0.399
2001 Fujii S, Shimizu K, Shimizu T, Lotze MT. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood. 98: 2143-51. PMID 11568001 DOI: 10.1182/Blood.V98.7.2143  0.367
2001 Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA. Ceramide mediates tumor-induced dendritic cell apoptosis. Journal of Immunology (Baltimore, Md. : 1950). 167: 3773-84. PMID 11564794 DOI: 10.4049/Jimmunol.167.7.3773  0.376
2001 Okada H, Villa L, Attanucci J, Erff M, Fellows W, Lotze M, Pollack I, Chambers W. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Therapy. 8: 1157-1166. PMID 11509946 DOI: 10.1038/Sj.Gt.3301496  0.383
2001 Shimizu T, Berhanu A, Redlinger RE, Watkins S, Lotze MT, Barksdale EM. Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. Journal of Pediatric Surgery. 36: 1285-92. PMID 11479878 DOI: 10.1053/Jpsu.2001.25796  0.41
2001 Won Ki Kang, Park C, Hyunah Lee Yoon, Won Seog Kim, Yoon SS, Lee MH, Park K, Kim K, Hyun Sik Jeong, Kim JA, Nam SJ, Yang JH, Son YI, Baek CH, Han J, ... ... Lotze MT, et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study Human Gene Therapy. 12: 671-684. PMID 11426466 DOI: 10.1089/104303401300057388  0.364
2001 Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, Yen SH, Lotze MT. Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology. 60: 110-5. PMID 11244324 DOI: 10.1159/000055306  0.332
2001 Iwazawa T, Chau GY, Mori T, Dookeran KA, Rubin JT, Watkins S, Robbins PD, Lotze MT, Tahara H. Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in liver metastasis model of rat: no additional benefit of using retroviral producer cell. Cancer Gene Therapy. 8: 17-22. PMID 11219489 DOI: 10.1038/Sj.Cgt.7700272  0.331
2001 Dallal RM, Lotze MT. Immunotherapy of Metastasis Surgical Oncology Clinics of North America. 10: 433-447. DOI: 10.1016/S1055-3207(18)30074-7  0.373
2001 Shimizu T, Relinger R, Lotze M, Barksdale E. Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma Current Surgery. 58: 503. DOI: 10.1016/S0149-7944(01)00522-0  0.377
2000 Esche C, Cai Q, Peron JM, Hunter O, Subbotin VM, Lotze MT, Shurin MR. Interleukin-12 and Flt3 ligand differentially promote dendropoiesis in vivo. European Journal of Immunology. 30: 2565-75. PMID 11009090 DOI: 10.1002/1521-4141(200009)30:9<2565::Aid-Immu2565>3.0.Co;2-V  0.387
2000 Dallal RM, Lotze MT. The dendritic cell and human cancer vaccines Current Opinion in Immunology. 12: 583-588. PMID 11007363 DOI: 10.1016/S0952-7915(00)00146-1  0.356
2000 Pirtskhalaishvili G, Shurin GV, Esche C, Cai Q, Salup RR, Bykovskaia SN, Lotze MT, Shurin MR. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. British Journal of Cancer. 83: 506-13. PMID 10945499 DOI: 10.1054/Bjoc.2000.1289  0.363
2000 Mailliard RB, Dallal RM, Son YI, Lotze MT. Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen. Immunological Investigations. 29: 177-85. PMID 10854187 DOI: 10.3109/08820130009062302  0.334
2000 Agha-Mohammadi S, Lotze MT. Regulatable systems: Applications in gene therapy and replicating viruses Journal of Clinical Investigation. 105: 1177-1183. PMID 10791990 DOI: 10.1172/Jci10027  0.309
2000 Agha-Mohammadi S, Lotze MT. Immunomodulation of cancer: Potential use of selectively replicating agents Journal of Clinical Investigation. 105: 1173-1176. PMID 10791989 DOI: 10.1172/Jci10026  0.445
2000 Okada H, Attanucci J, Tahara H, Pollack IF, Bozik ME, Chambers WH, Lotze MT. Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Therapy. 7: 486-94. PMID 10766355 DOI: 10.1038/Sj.Cgt.7700140  0.369
2000 Weigel TL, Lotze MT, Kim PK, Amoscato AA, Luketich JD, Odoux C. Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity Journal of Thoracic and Cardiovascular Surgery. 119: 795-803. PMID 10733772 DOI: 10.1016/S0022-5223(00)70016-X  0.324
2000 Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F, Schiff D, Attanucci J, Edington H, Chambers W, Robbins P, Baar J, Kinzler D, Whiteside T, Elder E. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Human Gene Therapy. 11: 637-53. PMID 10724042 DOI: 10.1089/10430340050015824  0.345
2000 Hiroishi K, Tüting T, Tahara H, Lotze MT. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models. Gene Therapy. 6: 1988-94. PMID 10637450 DOI: 10.1038/Sj.Gt.3301034  0.367
2000 Hiroishi K, Tüting T, Lotze MT. IFN-α-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs Journal of Immunology. 164: 567-572. PMID 10623796 DOI: 10.4049/Jimmunol.164.2.567  0.387
2000 Esche C, Subbotin VM, Hunter O, Peron JM, Maliszewski C, Lotze MT, Shurin MR. Differential regulation of epidermal and dermal dendritic cells by IL-12 and Flt3 ligand. The Journal of Investigative Dermatology. 113: 1028-32. PMID 10594747 DOI: 10.1046/J.1523-1747.1999.00779.X  0.353
2000 Egawa S, Mailliard R, Lotze MT. Peripheral blood monocytes derived dendritic cells generated with interferon-α and granulocyte-macrophage colony-stimulating factor are potent IL-12 producers Journal of the American College of Surgeons. 191. DOI: 10.1016/S1072-7515(00)00425-7  0.339
2000 Dallal RM, Son Y, Mailliard R, Lotze MT. Interleukin-18 markedly augments NK cell proliferation and cytotoxicity when combined with low-dose interleukin-2 Journal of the American College of Surgeons. 191: S16. DOI: 10.1016/S1072-7515(00)00417-8  0.318
1999 Osaki T, Hashimoto W, Gambotto A, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Therapy. 6: 808-15. PMID 10505105 DOI: 10.1038/Sj.Gt.3300908  0.366
1999 Esche C, Lokshin A, Shurin GV, Gastman BR, Rabinowich H, Watkins SC, Lotze MT, Shurin MR. Tumor's other immune targets: dendritic cells. Journal of Leukocyte Biology. 66: 336-44. PMID 10449178 DOI: 10.1002/Jlb.66.2.336  0.395
1999 Lotze MT. Not just an antigen-presenting cell: 5th International Symposium on Dendritic Cells in Fundamental and Clinical Immunology Journal of Leukocyte Biology. 66: 195-200. PMID 10449153 DOI: 10.1002/Jlb.66.2.195  0.339
1999 Okada H, Giezeman-Smits KM, Tahara H, Attanucci J, Fellows WK, Lotze MT, Chambers WH, Bozik ME. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Therapy. 6: 219-26. PMID 10435106 DOI: 10.1038/Sj.Gt.3300798  0.337
1999 Esche C, Gambotto A, Satoh Y, Gerein V, Robbins PD, Watkins SC, Lotze MT, Shurin MR. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. European Journal of Immunology. 29: 2148-55. PMID 10427977 DOI: 10.1002/(Sici)1521-4141(199907)29:07<2148::Aid-Immu2148>3.0.Co;2-F  0.393
1999 Tüting T, Gambotto A, DeLeo A, Lotze MT, Robbins PD, Storkus WJ. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Therapy. 6: 73-80. PMID 10078966 DOI: 10.1038/Sj.Cgt.7700020  0.35
1999 Douin-Echinard V, Robbins PD, Lotze MT, Favre G, Couderc B. Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70. Advances in Experimental Medicine and Biology. 451: 353-7. PMID 10026896 DOI: 10.1007/978-1-4615-5357-1_55  0.421
1999 Tüting T, Wilson CC, Martin DM, Baar J, DeLeo A, Lotze MT, Storkus WJ. DNA vaccines targeting dendritic cells for the immunotherapy of cancer. Advances in Experimental Medicine and Biology. 451: 295-304. PMID 10026887 DOI: 10.1007/978-1-4615-5357-1_46  0.404
1999 Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation. 66: 1567-74. PMID 9884241 DOI: 10.1097/00007890-199812270-00001  0.394
1999 Pirtskhalaishvili G, Salup RR, Esche C, Lotze MT, Shurin MR. Protection Of Human Dendritic Cells From Prostate Cancer-Induced Apoptosis By Il-12 And Il-15 The Journal of Urology. 126. DOI: 10.1097/00005392-199904010-00506  0.338
1999 Tanaka F, Hirao M, Lotze MT. Delivery of dendritic cells to sites of immune reactivity Clinical Immunology Newsletter. 19: 128-131. DOI: 10.1016/S0197-1859(00)87086-7  0.313
1998 Shurin GV, Gerein V, Lotze MT, Barksdale EM. Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand. Natural Immunity. 16: 263-74. PMID 11061594 DOI: 10.1159/000069452  0.397
1998 Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, Lotze MT, Chambers WH, Bozik ME. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. International Journal of Cancer. 78: 196-201. PMID 9754652 DOI: 10.1002/(Sici)1097-0215(19981005)78:2<196::Aid-Ijc13>3.0.Co;2-9  0.387
1998 Shurin MR, Esche C, Lotze MT. FLT3: Receptor and ligand. Biology and potential clinical application Cytokine and Growth Factor Reviews. 9: 37-48. PMID 9720755 DOI: 10.1016/S1359-6101(97)00035-X  0.363
1998 Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Archives of Otolaryngology--Head & Neck Surgery. 124: 641-6. PMID 9639473 DOI: 10.1001/Archotol.124.6.641  0.361
1998 Finn OJ, Lotze MT. Introduction: Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Journal of Immunotherapy. 21: 114-118. PMID 9551362 DOI: 10.1097/00002371-199803000-00004  0.316
1998 Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Annals of Surgery. 227: 398-404. PMID 9527063 DOI: 10.1097/00000658-199803000-00012  0.311
1998 Myers JN, Mank-Seymour A, Zitvogel L, Storkus W, Clarke M, Johnson CS, Tahara H, Lotze MT. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. The Laryngoscope. 108: 261-8. PMID 9473079 DOI: 10.1097/00005537-199802000-00019  0.398
1998 Takayama T, Nishioka Y, Lu L, Storkus WJ, Lotze MT, Tahara H, Thomson AW. VIRAL IL-10 GENE TRANSDUCTION MARKEDLY INHIBITS THE ALLOSTIMULATORY ACTIVITY OF DENDRITIC CELLS. Transplantation. 65: 258. DOI: 10.1097/00007890-199805131-00714  0.335
1998 Esche C, Lokshin A, Lotze MT, Shurin MR. Murine and human melanoma induces apoptosis of dendritic cells: A potential mechanism of tumor-induced immunosuppression Journal of Dermatological Science. 16: S159. DOI: 10.1016/S0923-1811(98)83948-0  0.369
1998 Péron J, Subbotin V, Haluszczak C, Lotze M, Shurin. The anti-tumor effect of FLT3-ligand administration on murine liver metastases is mediated in part by NK cells Gastroenterology. 114. DOI: 10.1016/S0016-5085(98)85364-X  0.336
1997 Elder EM, Lotze MT, Whiteside TL. Methods for generation of genetically modified fibroblasts for immunotherapy of cancer. Methods in Molecular Medicine. 7: 349-56. PMID 24493439 DOI: 10.1385/0-89603-484-4:349  0.399
1997 Tüting T, Gambotto A, Baar J, Davis ID, Storkus WJ, Zavodny PJ, Narula S, Tahara H, Robbins PD, Lotze MT. Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models Gene Therapy. 4: 1053-1060. PMID 9415311 DOI: 10.1038/Sj.Gt.3300509  0.385
1997 Tüting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. European Journal of Immunology. 27: 2702-7. PMID 9368629 DOI: 10.1002/Eji.1830271033  0.381
1997 Lotze MT, Shurin M, Davis I, Amoscato A, Storkus WJ. Dendritic cell based therapy of cancer. Advances in Experimental Medicine and Biology. 417: 551-69. PMID 9286419 DOI: 10.1007/978-1-4757-9966-8_91  0.389
1997 Tüting T, Zorina T, Ma DI, Wilson CC, De Cesare CM, De Leo AB, Lotze MT, Storkus WJ. Development of dendritic cell-based genetic vaccines for cancer. Advances in Experimental Medicine and Biology. 417: 511-8. PMID 9286412 DOI: 10.1007/978-1-4757-9966-8_84  0.371
1997 Wilson CC, Tueting T, Ma D, Haluszczak C, Lotze M, Storkus W. Activation of Dendritic Cells by Surrogate T Cell Interactions Leads to Enhanced Costimulation, Secretion of TH1-Associated Cytokines, and CTL Inductive Capacity Advances in Experimental Medicine and Biology. 417: 335-343. PMID 9286383 DOI: 10.1007/978-1-4757-9966-8_55  0.363
1997 Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O, Brumfield A, Storkus WJ, Maraskovsky E, Lotze MT. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cellular Immunology. 179: 174-84. PMID 9268501 DOI: 10.1006/Cimm.1997.1152  0.359
1997 Tüting T, Storkus WJ, Lotze MT. Gene-based strategies for the immunotherapy of cancer Journal of Molecular Medicine. 75: 478-491. PMID 9253711 DOI: 10.1007/S001090050133  0.419
1997 Maeurer MJ, Lotze MT. Tumor recognition by the cellular immune dystem: New aspects of tumor immunology International Reviews of Immunology. 14: 97-132. PMID 9131383 DOI: 10.3109/08830189709116848  0.339
1997 Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, Lotze MT. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells (Dayton, Ohio). 15: 94-103. PMID 9090785 DOI: 10.1002/Stem.150094  0.39
1997 Maeurer MJ, Walter W, Martin D, Zitvogel L, Elder E, Storkus W, Lotze MT. Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scandinavian Journal of Immunology. 45: 182-92. PMID 9042431 DOI: 10.1046/J.1365-3083.1997.D01-384.X  0.366
1997 Zitvogel L, Couderc B, Mayordomo JI, Robbins PD, Lotze MT, Storkus WJ. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Annals of the New York Academy of Sciences. 795: 284-93. PMID 8958940 DOI: 10.1111/J.1749-6632.1996.Tb52678.X  0.388
1997 Tahara H, Zitvogel L, Storkus WJ, Robbins PD, Lotze MT. Murine models of cancer cytokine gene therapy using interleukin-12. Annals of the New York Academy of Sciences. 795: 275-83. PMID 8958939 DOI: 10.1111/J.1749-6632.1996.Tb52677.X  0.409
1997 Lotze MT, Storkus WJ, Falo L, Baar J, Davis I, Tueting T, Esche C, Whiteside TL, Elder EM, Kinzler DM, Paradise C, Kirkwood JM. Dendritic cells (DCs) and the immunotherapy of melanoma Melanoma Research. 7: S4. DOI: 10.1097/00008390-199706001-00012  0.321
1997 Nishioka Y, Shurin M, Robbins PD, Storkus WJ, Lotze MT, Tahara H. EFFECTIVE TUMOR IMMUNOTHERAPY USING BONE MARROW (BM)-DERIVED DENDRITIC CELLS (DCS) GENETICALLY ENGINEERED TO EXPRESS INTERLEUKIN 12 Journal of Immunotherapy. 20: 419. DOI: 10.1097/00002371-199709000-00090  0.326
1997 Osaki T, Péron J-, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H. ANALYSES ON ANTI-TUMOR EFFECTS OF INTERFERON-γ-INDUCING FACTOR/INTERLEUKIN-18 AGAINST MURINE TUMORS Journal of Immunotherapy. 20: 417. DOI: 10.1097/00002371-199709000-00082  0.335
1997 Tahara H, Elder EM, Cai O, Kinzler DM, Storkus WJ, Zitvogel L, Kirkwood JM, Whiteside TL, Robbins PD, Lotze MT. PHASE I CLINICAL TRIAL OF INTERLEUKIN-12 (IL-12) CYTOKINE GENE THERAPY WITH OBJECTIVE RESPONSES IN CANCER PATIENTS WITH VARIOUS HISTOLOGIES Journal of Immunotherapy. 20: 416. DOI: 10.1097/00002371-199709000-00078  0.317
1997 Elder EM, Lotze MT, Whiteside TL. CULTURE ON HUMAN DENDRITIC CELLS (DC) FOR THERAPY OF PATIENTS WITH CANCER Journal of Immunotherapy. 20: 407. DOI: 10.1097/00002371-199709000-00042  0.322
1997 Campbell RL, Repasky EA, Lotze MT. T-CELL SPECTRIN (FODRIN) AGGREGATION AND UROPOD FORMATION FOLLOWING DENDRITIC CELL ENCOUNTER Journal of Immunotherapy. 20: 405. DOI: 10.1097/00002371-199709000-00035  0.307
1997 Hall TD, Kinzler DM, Elder EM, Whiteside TL, Storkus WJ, Lotze MT. EVALUATION AND RESPONSE OF PATIENTS IMMUNIZED TO HLA-A2 POLYPEPITOPE PEPTIDE MIXTURE IN PATIENTS WITH METASTATIC MELANOMA USING AUTOLOGOUS DENDRITIC CELLS CULTURED WITH IL-4 AND GM-CSF Journal of Immunotherapy. 20: 405. DOI: 10.1097/00002371-199709000-00033  0.32
1997 Shurin MR, Esche C, Lokshin A, Lotze MT. TUMORS INDUCE APOPTOSIS OF DENDRITIC CELLS IN VITRO. Journal of Immunotherapy. 20: 403. DOI: 10.1097/00002371-199709000-00025  0.376
1997 Hunter O, Haluszczak C, Subbotin VM, Lotze MT, Shurin MR. ADMINISTRATION OF IL-12 AND FL T3 LIGAND ENHANCES MURINE DENDRITIC CELL GENERATION Journal of Immunotherapy. 20: 401. DOI: 10.1097/00002371-199709000-00016  0.33
1997 Kinzler D, Tahara H, Elder E, Johnson C, Nguyen N, Hanan S, Thomas R, Vu H, Duran P, Kirkwood J, Lotze M. PATIENT RECRUITMENT ONTO A PHASE I CLINICAL TRIAL OF INTERLEUKIN 12 (IL-12) GENE THERAPY FOR CANCER Journal of Immunotherapy. 20: 400. DOI: 10.1097/00002371-199709000-00012  0.304
1997 Numasaki M, Lotze MT, Tahara H. INTERLEUKIN 17 GENE TRANSFECTION INTO MURINE FIBROSARCOMA CELL LINE MCA 205 INCREASES TUMORIGENICITY CORRELATED WITH ENHANCED TUMOR MICROVASCULARITY Journal of Immunotherapy. 20: 399. DOI: 10.1097/00002371-199709000-00011  0.35
1997 Kim SH, An CS, Tahara H, Park CH, Lotze MT, Robbins PD, Kim S. Retroviral-mediated IL-12 gene therapy for advanced murine tumors Experimental & Molecular Medicine. 29: 53-58. DOI: 10.1038/Emm.1997.8  0.377
1997 Park C, Kang W, Oh M, Kim WS, Yang J, Lotze MT, Kim S, Park K, Park CH. Production of IL-12 from gene modified human dermal fibroblasts: A preclinical study for IL-12 cancer gene therapy Experimental & Molecular Medicine. 29: 65-69. DOI: 10.1038/Emm.1997.10  0.311
1997 Tüting T, Baar J, Schurin M, Mayordomo JI, Zitvogel L, Tahara H, Storkus WJ, DeLeo A, Lotze MT. Dendritic cell-based therapy for cancer European Journal of Cancer. 33: S21. DOI: 10.1016/S0959-8049(97)89384-7  0.328
1996 Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. The Journal of Clinical Investigation. 98: 1633-41. PMID 8833913 DOI: 10.1172/Jci118958  0.388
1996 Elder EM, Lotze MT, Whiteside TL. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Human Gene Therapy. 7: 479-87. PMID 8800742 DOI: 10.1089/Hum.1996.7.4-479  0.341
1996 Bernhard H, Maeurer MJ, Jäger E, Wölfel T, Schneider J, Karbach J, Seliger B, Huber C, Storkus WS, Lotze MT, Meyer zum Büschenfelde KH, Knuth A. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma. Scandinavian Journal of Immunology. 44: 285-92. PMID 8795723 DOI: 10.1046/J.1365-3083.1996.D01-304.X  0.302
1996 Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of a synthetic mucin peptide vaccine: Induction of specific immune reactivity in patients with adenocarcinoma Journal of Surgical Research. 63: 298-304. PMID 8667619 DOI: 10.1006/Jsre.1996.0264  0.301
1996 Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines Journal of Experimental Medicine. 183: 1357-1365. PMID 8666894 DOI: 10.1084/Jem.183.4.1357  0.352
1996 Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Human Gene Therapy. 6: 1607-24. PMID 8664385 DOI: 10.1089/Hum.1995.6.12-1607  0.316
1996 Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. European Journal of Immunology. 26: 1335-41. PMID 8647214 DOI: 10.1002/Eji.1830260624  0.397
1996 Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based peptide vaccines Melanoma Research. 6: 11-24. PMID 8640065 DOI: 10.1097/00008390-199602000-00003  0.323
1996 Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. The Journal of Experimental Medicine. 183: 87-97. PMID 8551248 DOI: 10.1084/Jem.183.1.87  0.401
1996 Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. The Journal of Experimental Medicine. 183: 283-7. PMID 8551233 DOI: 10.1084/Jem.183.1.283  0.39
1996 Shurin MR, Maraskowsky E, Lotze MT. FLT3-LIGAND INHIBITS TUMOR PROGRESSION IN MURINE MODEL Journal of Immunotherapy. 19: 466. DOI: 10.1097/00002371-199611000-00049  0.305
1996 Bozik ME, Lotze MT, Chambers WH. Effective Treatment Of Cns Tumor With Il-4 Producing Glioma Vaccine Journal of Immunotherapy. 19: 464. DOI: 10.1097/00002371-199611000-00044  0.314
1996 Berman RM, Rilo HL, Hoehnke C, Shurin MR, Narula SK, Maraskovsky E, Lotze MT. Interleukin-10 Effects On In Vivo Generation And In Vitro Function Of Dendritic Cells Journal of Immunotherapy. 19: 464. DOI: 10.1097/00002371-199611000-00042  0.322
1996 Cai O, Preskey D, Robbins PD, Lotze MT, Tahara H. INTERLUKIN-12 (IL-12) EXPRESSION AT THE TUMOR SITE IS CRITICAL IN NATURAL TUMOR REJECTION BUT NOT IN MOUSE IL-10 MEDIATED ANTI-TUMOR EFFECTS Journal of Immunotherapy. 19: 464. DOI: 10.1097/00002371-199611000-00041  0.356
1995 Pappo I, Tahara H, Robbins PD, Gately MK, Wolf SF, Barnea A, Lotze MT. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. The Journal of Surgical Research. 58: 218-26. PMID 7861776 DOI: 10.1006/Jsre.1995.1034  0.36
1995 Zitvogel L, Tahara H, Cai Q, Storkus WJ, Muller G, Wolf SF, Gately M, Robbins PD, Lotze MT. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Human Gene Therapy. 5: 1493-506. PMID 7711142 DOI: 10.1089/Hum.1994.5.12-1493  0.38
1995 Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, Lotze MT. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunology, Immunotherapy : Cii. 41: 111-21. PMID 7656270 DOI: 10.1007/Bf01527407  0.405
1995 Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MT. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. The Journal of Experimental Medicine. 182: 477-86. PMID 7629507 DOI: 10.1084/Jem.182.2.477  0.404
1995 Suminami Y, Elder EM, Lotze MT, Whiteside TL. In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 17: 238-48. PMID 7582260 DOI: 10.1097/00002371-199505000-00006  0.317
1994 Hunt JD, Pippin BA, Landreneau RJ, Jacob WF, Lotze MT, Siegfried JM. Transfer and expression of the human interleukin-4 gene in carcinoma and stromal cell lines derived from lung cancer patients. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 14: 314-21. PMID 8280714 DOI: 10.1097/00002371-199311000-00011  0.397
1994 Oppenheim MH, Lotze MT. Interleukin-2: solid-tumor therapy. Oncology. 51: 154-69. PMID 8196899 DOI: 10.1159/000227330  0.374
1994 Zeh HJ, Hurd S, Storkus WJ, Lotze MT. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 14: 155-61. PMID 7904180 DOI: 10.1097/00002371-199308000-00012  0.397
1994 Zitvogel L, Tahara H, Robbins P, Clark M, Lotze MT. B7.1 EXPRESSION ENHANCES EFFECTIVE IL-12 MEDIATED ANTITUMOR IMMUNITY Journal of Immunotherapy. 16: 247. DOI: 10.1097/00002371-199410000-00059  0.327
1994 Tahara H, Zitvogel L, Storkus WJ, McKinney TG, Robbins PD, Lotze MT. CANCER GENE THERAPY USING INTERLEUKIN-12 (IL-12) Journal of Immunotherapy. 16: 245. DOI: 10.1097/00002371-199410000-00053  0.313
1994 Suzuki T, Tahara H, Robbins PD, Lotze MT. DISCORDANT BIOLOGIC EFFECTS OF VIRAL IL-10 AND AUTHENTIC IL-10 IN MURINE TUMOR MODELS Journal of Immunotherapy. 16: 245. DOI: 10.1097/00002371-199410000-00051  0.319
1994 Suminami Y, Elder EM, Lotze MT, Whiteside TL. QUANTITATIVE PCR FOR EXPRESSION OF THE IL4 GENE IN BIOPSIES OF PATIENTS RECEIVING GENETICALLY-MODIFIED TUMOR VACCINE Journal of Immunotherapy. 16: 244. DOI: 10.1097/00002371-199410000-00050  0.311
1994 Berman R, Suzuki T, Tahara H, Robbins P, Lotze M. Human and viral interleukin-10 (hIL-10 and vIL-10) mediate opposing effects in tumor immunity Cytokine. 6: 571. DOI: 10.1016/1043-4666(94)90276-3  0.355
1993 Lotze MT. Transplantation and Adoptive Cellular Therapy of Cancer: The Role of T-Cell Growth Factors Cell Transplantation. 2: 33-47. DOI: 10.1177/096368979300200106  0.308
1993 Cai O, Elder E, Whiteside T, Rubin J, Moen R, Lotze MT. Tracking Genetically Marked Tumor Infiltrating Lymphocytes In Vivo In Il-2 And Il-4 Treated Melanoma Patients Using Pcr Journal of Immunotherapy. 14: 368. DOI: 10.1097/00002371-199311000-00061  0.335
1993 Zitvogel L, Tahara H, Robbins PD, Lotze MT. EFFICIENT EXPRESSION OF IL12 AFTER TRANSDUCTION OF TUMOR CELLS WITH A RETROVIRAL VECTOR ENCODING BOTH SUBUNITS OF HUMAN IL12 Journal of Immunotherapy. 14: 364. DOI: 10.1097/00002371-199311000-00046  0.344
1993 Pippin BA, Kuebbing D, Nishihara K, Hurd SD, Lotze MT. TRANSFECTION OF INTERLEUKIN-4 INTO FIBRO-BLASTS FOR CYTOKINE GENE THERAPY OF CANCER Journal of Immunotherapy. 13: 69. DOI: 10.1097/00002371-199301000-00048  0.31
1993 Berman RM, Zeh HJ, Storkus WJ, Lotze MT. INTERLEUKIN-10 INDUCES LYMPHOKINE-ACTIVATED KILLER (LAK) CELL ACTIVITY Journal of Immunotherapy. 13: 56. DOI: 10.1097/00002371-199301000-00011  0.319
1992 Lotze MT, Zeh HJ, Elder EM, Cai Q, Pippin BA, Rosenstein MM, Whiteside TL, Herberman R. Use of T-cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 12: 212-7. PMID 1359903 DOI: 10.1097/00002371-199210000-00015  0.386
1992 Pippin B, Cai Q, Lotze MT. EVALUATION OF IMMUNE REACTIVITY TO IL-2 TRANSFECTED TUMORS Journal of Immunotherapy. 11: 137. DOI: 10.1097/00002371-199202000-00045  0.363
1992 Lotze MT, Rubin JT, Zeh HJ. New biologic agents come to bat for cancer therapy Current Opinion in Oncology. 4: 1108-1123. DOI: 10.1097/00001622-199212000-00017  0.39
1990 Lotze MT, Finn OJ. Recent advances in cellular immunology: implications for immunity to cancer. Immunology Today. 11: 190-3. PMID 2354026 DOI: 10.1016/0167-5699(90)90079-O  0.348
1990 Custer MC, Lotze MT. A biologic assay for IL-4 rapid fluorescence assay for IL-4 detection in supernatants and serum Journal of Immunological Methods. 128: 109-117. PMID 2139081 DOI: 10.1016/0022-1759(90)90469-C  0.331
1987 Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Annals of Internal Medicine. 107: 293-300. PMID 3497595 DOI: 10.7326/0003-4819-107-2-293  0.34
1987 Lotze MT, Roberts K, Custer MC, Segal DA, Rosenberg SA. Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors. The Journal of Surgical Research. 42: 580-9. PMID 3495699 DOI: 10.1016/0022-4804(87)90036-9  0.38
1987 Skibber JM, Lotze MT, Uppenkamp I, Ross W, Rosenberg SA. Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer. The Journal of Surgical Research. 42: 613-21. PMID 3295393 DOI: 10.1016/0022-4804(87)90004-7  0.316
1987 Lotze MT, Rosenberg SA. In Reply Jama: the Journal of the American Medical Association. 257: 1730-1731. DOI: 10.1001/Jama.1987.03390130047019  0.363
1985 Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer. 55: 1327-33. PMID 3871657 DOI: 10.1002/1097-0142(19850315)55:6<1327::Aid-Cncr2820550628>3.0.Co;2-O  0.33
Show low-probability matches.